Skip to main content
. Author manuscript; available in PMC: 2015 Nov 17.
Published in final edited form as: BJU Int. 2010 Sep 21;107(5):741–747. doi: 10.1111/j.1464-410X.2010.09626.x

Table 3.

Therapies (N=28)

Prior Therapies N (%)

Chemotherapy (gemcitabine+adriamycin, followed by carboplatinum plus paclitaxel) 1 (3.57)

Interferon alfa 4 (14.29)

TKI: 15 (53.57)
Sunitinib alone 4
Sorafenib alone 2
Sorafenib plus interferon 2
Sequential sorafenib and sunitinib 4
Bevacizumab plus erlotinib only 2
Bevacizumab plus erlotinib followed by sunitinib 1

None 10 (35.71)

Post Therapies

TKI 11 (39.29)

Other (interferon, temsirolimus, and thalidomide) 3 (10.71)